key: cord-0265225-uo6rqhjh authors: Kjellberg, A.; Abdel-Halim, L.; Hassler, A.; El Gharbi, S.; Al-Ezerjawi, S.; Boström, E.; Sundberg, C. J.; Pernow, J.; Medson, K.; Kowalski, J.; Rodriguez-Wallberg, K. A.; Zheng, X.; Catrina, S. B.; Runold, M.; Stahlberg, M.; Bruchfeld, J.; Nygren-Bonnier, M.; Lindholm, P. title: Hyperbaric Oxygen for Treatment of Long COVID Syndrome (HOT-LoCO); Protocol for a Randomised, Placebo-Controlled, Double-Blind, Phase II Clinical Trial date: 2022-05-20 journal: nan DOI: 10.1101/2022.05.20.22275312 sha: 26faf2f427adadb161ba970cce28402416d4ba1c doc_id: 265225 cord_uid: uo6rqhjh Introduction Long COVID, where symptoms persist 12 weeks after the initial SARS-CoV-2-infection, is a substantial problem for individuals and society in the surge of the pandemic. Common symptoms are fatigue, post-exertional malaise, and cognitive dysfunction. There is currently no effective treatment, and the underlying mechanisms are unknown although several hypotheses exist, with chronic inflammation as a common denominator. In prospective studies, hyperbaric oxygen therapy (HBOT) has been suggested to be effective for the treatment of similar syndromes such as chronic fatigue syndrome and fibromyalgia. A case series has suggested positive effects of HBOT in Long COVID. This randomised placebo-controlled clinical trial will explore HBOT as a potential treatment for Long COVID. The primary objective is to evaluate if HBOT improves health related quality of life (HRQoL) for patients with Long COVID compared to placebo/sham. The main secondary objectives are to evaluate whether HBOT improves endothelial function, objective physical performance, and short term HRQoL. Methods and Analysis A randomised, placebo-controlled, double-blind, phase II clinical trial in 80 previously healthy subjects debilitated due to Long COVID, with low HRQoL. Clinical data, HRQoL-questionnaires, blood samples, objective tests and activity meter data will be collected at baseline. Subjects will be randomised to a maximum of 10 treatments with hyperbaric oxygen or sham treatment over six weeks. Assessments for safety and efficacy will be performed at six, 13, 26 and 52 weeks, with the primary endpoint (physical domains in RAND-36) and main secondary endpoints defined at 13 weeks after baseline. Data will be reviewed by an independent Data Safety Monitoring Board. Ethics and Dissemination The trial is approved by The Swedish National Institutional Review Board (2021-02634) and the Swedish Medical Product Agency (5.1-2020-36673). Positive, negative, and inconclusive results will be published in peer-reviewed scientific journals with open access. Trial Registration NCT04842448. EudraCT: 2021-000764-30 Strengths and limitations of this trial Strengths -Randomised placebo-controlled, double-blind, parallel groups, clinical trial in compliance with ICH-GCP -Evaluation of safety and efficacy, including objective and explanatory endpoints -Independent Data Safety Monitoring Board (DSMB) Limitations -New syndrome with unknown mechanisms -Power calculation is based on similar syndromes -Selection bias as patients are enrolled from the same post-COVID clinic . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) o r g a n i s a t i o n ( W H O ) , w a s r e c e n t l y m a d e b y a D e l p h i c o n s e n s u s p r o c e s s 8 . P o s t C O V I D c o n d i t i o n i s p r e v i o u s l y l i s t e d i n I n t e r n a t i o n a l C l a s s i f i c a t i o n o f D i s e a s e s ( I C D -1 0 ) w i t h c o d e U 0 9 . 9 , w h i c h i n c l u d e s a l l c o m m o n l y u s e d n a m e s . E x p e r t s i n t h e f i e l d h a v e r e c e n t l y s u g g e s t e d m a n a g e m e n t g u i d e l i n e s f o r m o n i t o r i n g a n d f o l l o w -u p , b u t t o d a t e t h e r e i s n o e f f e c t i v e t r e a t m e n t 9 . T h e u n d e r l y i n g m e c h a n i s m s a r e n o t u n d e r s t o o d b u t s e v e r a l h y p o t h e s e s i n c l u d i n g e n d o t h e l i a l d y s f u n c t i o n , o x i d a t i v e s t r e s s , a n d c h r o n i c i n f l a m m a t i o n h a v e b e e n p r o p o s e d 1 0 1 1 . I n f a c t , a r e c e n t s t u d y d e m o n s t r a t e d p e r s i s t e n t m i c r o v a s c u l a r e n d o t h e l i a l d y s f u n c t i o n f o r f o u r m o n t h s f o l l o w i n g C O V I D -1 9 i n f e c t i o . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 20, 2022 . h a t r e s u l t i n d i f f i c u l t y u n d e r s t a n d i n g t h e m e a n i n g o f t r i a l p a r t i c i p a t i o n T r e a t m e n t / i n t e r v e n t i o n . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 20, 2022. ; https://doi.org/10.1101/2022.05.20.22275312 doi: medRxiv preprint 1 . T h e p h y s i c a l d o m a i n s s e e m t o b e s e v e r e l y a f f e c t e d i n c o n d i t i o n s a s s o c i a t e d w i t h c h r o n i c f a t i g u e a n d P O T S 2 4 2 5 . 2 . W e e x p e c t t h e p h y s i c a l d o m a i n s t o b e l e a s t a f f e c t e d b y p l a c e b o . E u r o Q o l -5 D i m e n s i o n s Q u e s t i o n n a i r e ( E Q - . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 20, 2022. o t h e l i a l f u n c t i o n w i l l b e d e t e r m i n e d i n f a s t i n g s t a t e u s i n g a n E n d o P A T 2 0 0 0 d e v i c e ( I t a m a r M e d i c a l , C a e s a r e a , I s r a e l ) . T h e s u b j e c t s w i l l b e c o n n e c t e d t o t h e p u l s e a m p l i t u d e t o n o m e t r y ( P A T ) d e v i c e f o r n o n -i n v a s i v e d e t e r m i n a t i o n o f d i g i t a l e n d o t h e l i a l f u n c t i o n . T h e P A T d e v i c e c o m p r i s e s a p n e u m a t i c p l e t h y s m o g r a p h t h a t a l l o w s m e a s u r e m e n t s o f p u l s e a m p l i t u d e a t b a s e l i n e a n d d u r i n g h y p e r e m i a f o l l o w i n g a f i v e m i n u t e s a r t e r i a l o c c l u s i o n o f t h e f o r e a r m 3 0 . T h e c h a n g e i n t h e P A T s i g n a . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 20, 2022 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 20, 2022 p r e d e t e r m i n e d i n t e r i m a n a l y s e s a n d a t t h e e n d o f t r i a l , a c h a r t e r d e l i n e a t i n g t h e i r g u i d e l i n e s f o r o p e r a t i n g a n d s t o p p i n g r u l e s f o r t e r m i n a t i n g i n d i v i d u a l s u b j e c t s , a p o r t i o n o r a l l t h e t r i a l p r e m a t u r e l y , w a s d r a w n u p a n d a g r e e d u p o n b e f o r e t h e t r i a l s t a r t e d . T h e m e m b e r s o f t h e D S M B , m e e t i n g p l a n a n d r e s p o n s i b i l i t i e s a r e s p e c i f i e d i n t h e o r i g i n a l p r o t o c o l ( p . 6 a n d 4 4 ) . . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 20, 2022. ; https://doi.org/10.1101/2022.05.20.22275312 doi: medRxiv preprint I n g e n e r a l , f o r c o n t i n u o u s o u t c o m e v a r i a b l e s i n c l u d i n g t h e p r i m a r y e n d p o i n t , t h e y w i l l b e a n a l y s e d u s i n g A N C O V A , u n l e s s o t h e r w i s e s p e c i f i e d , i n c l u d i n g s t r a t i f i c a t i o n f a c t o r s a n d t r e a t m e n t a s f i x e d f a c t o r s i n t h e m o d e l . E s t i m a t e s w i l l b e p r e s e n t e d u s i n g l e a s t -s q u a r e m e a n s f o r d i f f e r e n c e s b e t w e e n t r e a t m e n t a r m s . I n a d d i t i o n , c o n t i n u o u s e n d p o i n t s m e a s u r e d r e p e a t e d l y o v e r t i m e , s u c h a s E Q 5 D a n d R A N D -3 6 d o m a i n s , t h e c h a n g e f r o m b a s e l i n e w i l l b e a n a l y z e d u s i n g a l i n e a r m i x e d -e f f e c t m o d e l i n c l u d i n g b a s e l i n e , t r e a t m e n t g r o u p , s e x , s y m p t o m s e v e r i t y , v i s i t , a n d t r e a t m e n t g r o u p b y v i s i t i n t e r a c t i o n , a n d s u b j e c t s a s r a n d o m e f f e c . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 20, 2022 L i m i t a t i o n s T h e c u r r e n t t r i a l h a s s o m e i m p o r t a n t l i m i t a t i o n s . L o n g C O V I D i s a n o v e l d i s e a s e w i t h u n k n o w n m e c h a n i s m s . T h e p r e v a l e n c e i s c o n t i n u o u s l y b e i n g r e v i s e d a n d i t i s n o t k n o w n h o w s y m p t o m s a n d b e s t p r a c t i c e t r e a t m e n t w i l l e v o l v e o v e r t i m e . T h e t r e a t m e n t p r o t o c o l i n t h i s t r i a l i s n o v e l a n d t h u T h e t r i a l i s m o n i t o r e d b y t h e K a r o l i n s k a T r i a l A l l i a n c e ( K T A ) b e f o r e t h e t r i a l s t a r t e d , d u r i n g t h e t r i a l , a n d a f t e r t r i a l c o m p l e t i o n . A d e s i g n a t e d m o n i t o r w i l l m o n i t o r t h e r a n d o m i s a t i o n a n d b l i n d i n g p r o c e s s . T h e m o n i t o r i n g i s p e r f o r m e d t o e n s u r e t h a t t h e t r i a l i s c o n d u c t e d i n c o m p l i a n c e w i t h t h e p r o t o c o l , d e t a i l e d i n a s e p a r a t e m o n i t o r i n g p l a n a n d t h a t d a t a i s h a n d l e d a c c o r d i n g t o I C H -G C P . T A K i s t h e p r i n c i p a l i n v e s t i g a t o r w h o w r o t e t h e h y p o t h e s i s a n d d e v e l o p e d m o s t o f t h e p r o t o c o l t o g e t h e r w i t h P L . A K a n d P L w r o t e t h e a p p l i c a t i o n s t o S w e d i s h I R B a n d M P A . L A H d r a f t e d t h e m a n u s c r i p t t o g e t h e r w i t h A K . A H , S E G , S A E a n d E B a r e s u b -i n v e s t i g a t o r s , e n r o l l i n g a n d e v a l u a t i n g s u b j e c t s a n d c o l l e c t i n g d a t a . M N B , J B , M S , a n d M R a r e t r i a l c h a i r s i n v o l v e d i n w r i t i n g t h e p r o t o c o l a n d a p p l i c a t i o n s . J K w r o t e t h e s t a t i s t i c a l a n a l y s i s p l a n t o g e t h e r w i t h A K a n d d e s i g n e d t . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. L i n a A b d e l -H a l i m 0 0 0 0 -0 0 0 2 -5 1 9 4 -6 4 3 2 A d r i a n H a s s l e r 0 0 0 0 -0 0 0 2 -5 7 9 6 -1 8 0 1 S a r a E l G h a r b i 0000-0002-0632-1839 S a r a h A l -E z e r j a w i 0 0 0 0 -0 0 0 2 -5 9 4 0 -6 1 8 2 E m i l B o s t r ö m 0 0 0 0 -0 0 0 1 -6 9 2 2 -7 6 3 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 20, 2022. ; https://doi.org/10.1101/2022.05.20.22275312 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 20, 2022. ; https://doi.org/10.1101/2022.05.20.22275312 doi: medRxiv preprint Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? Characterizing Long COVID: Deep Phenotype of a Complex Condition Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508 Characterizing long COVID in an international cohort: 7 months of symptoms and their impact Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome: The Swedish Experience Post-Covid-19 Tachycardia Syndrome: A distinct phenotype of Post-acute Covid-19 Syndrome NICE guideline on long COVID. The lancet Respiratory medicine A clinical case definition of post-COVID-19 condition by a Delphi consensus Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline HIF-1, the Warburg Effect, and Macrophage/Microglia Polarization Potential Role in COVID-19 Pathogenesis SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress Erythrocytes Induce Vascular Dysfunction in COVID-19 The effects of hyperbaric oxygen therapy (HBOT) on coronavirus disease-2019 (COVID-19): a systematic review Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial Randomised, controlled, open label, multicentre clinical trial to explore safety and efficacy of hyperbaric oxygen for preventing ICU admission, morbidity and mortality in adult patients with COVID-19 Can hyperbaric oxygen safely serve as an antiinflammatory treatment for COVID-19? COVID-19, acute respiratory distress syndrome (ARDS), and hyperbaric oxygen therapy (HBOT): what is the link? Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial Hyperbaric oxygen therapy can diminish fibromyalgia syndrome--prospective clinical trial The efficacy of hyperbaric oxygen therapy in the management of chronic fatigue syndrome Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension The Swedish RAND-36 Health Survey -reliability and responsiveness assessed in patient populations using Svensson's method for paired ordinal data Health-related quality of life in patients with chronic fatigue syndrome: an international study Sleep disturbances and diminished quality of life in postural tachycardia syndrome Modeling valuations for EuroQol health states Swedish experience-based value sets for EQ-5D health states The six-minute walk test Nexfin noninvasive continuous hemodynamic monitoring: validation against continuous pulse contour and intermittent transpulmonary thermodilution derived cardiac output in critically ill patients Assessment of endothelial function using digital pulse amplitude tonometry Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis The Promise of Sleep: A Multi-Sensor Approach for Accurate Sleep Stage Detection Using the Oura Ring Double-blind trials in hyperbaric medicine: A narrative review on past experiences and considerations in designing sham hyperbaric treatment Hyperbaric Oxygen Therapy: Side Effects Defined and Quantified Sham controls in medical device trials Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II